EASL | The Home of Hepatology’s Post

If you have not heard about the Global NASH Council, which includes a group of 140 international leaders in MASLD and MASH, this data will impress you. "The Global NASH Council (GNC) and Global Liver Council members have consistently demonstrated exceptional academic productivity, producing a substantial body of high-impact evidence in liver disease and NAFLD/MASLD. Our influential work has not only garnered widespread recognition but has also inspired and influenced the research directions. In the latest data from ScholarGPS (2022), our members have been ranked at the top of the field of liver disease, NAFLD, fatty liver disease and hepatology. Highly Ranked Scholars™-Lifetime are eminent authors whose Top Percentage Ranks places them above 0.05% of all scholars due to highly significant impact and quality of their scholarly contributions based on lifetime contributions." Ranking Scholar Report: #1 Zobair Younossi #2 Arun Sanyal #11 Elisabetta Bugianesi #16 Stephen A. Harrison #22 Giulio Marchesini #26 Luca Valenti #28 Rohit Loomba #34 Quentin M. Anstee #35 Kenny Cusi #36 Jacob George #39 Jian-Gao Fan #50 Massimo Colombo #51 Michael Trauner #58 Yusuf Yilmaz

#recentpublication Clonal Hematopoiesis is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF. #CH #HFpEF #WashU #ErrorCorrectedSequencing #NGS #Genomics #AHA #circulation https://lnkd.in/dN7ZP46w

🔬 Exciting News! 📚 Thrilled to announce that a research paper from our group in IRCCS Policlinico di Sant’Orsola - Azienda Ospedaliero Universitaria di Bologna has been accepted by the Journal of Clinical Medicine (JCM) MDPI 🎉📄 💥 AUTOIMMUNE POLYENDOCRINE SYNDROMES IN ADULT ITALIAN CELIAC DISEASE PATIENTS💥 In this study, we delved into the prevalence of #autoimmune #polyendocrine syndromes in a cohort of patients with #celiac disease. Our findings emphasize the importance of a multidisciplinary management strategy for celiac patients, recognizing the intricate connections between different autoimmune conditions. 🔍 Understanding the "mosaic of autoimmunity" opens new avenues for comprehensive patient care and sheds light on the complex interplay of various autoimmune disorders within the same individual. 🤝 Grateful for the collaboration with fellow researchers and the support of our institution throughout this journey. Special thanks to the "Journal of Clinical Medicine" for providing a platform to share our insights. 📌 Looking forward to contributing more to the field of autoimmune research and advancing patient-centred approaches to healthcare. 💪🏼👩🔬👨⚕️ Free full text: https://lnkd.in/dMx2wDPu #Research #Autoimmunity #CeliacDisease #ClinicalMedicine #Healthcare #MedicalResearch #familyofautoimmunity #mosaicofautoimmunity

Researchers at St. Joseph's Healthcare Hamilton recently published an article in the Journal of Biological Chemistry highlighting the importance of a liver protein known as TDAG51, which is naturally expressed in healthy liver. TDAG51 was shown to be severely reduced in Non-Alcoholic Steatohepatitis (NASH) patient liver biopsies. Tamana Yousof, a PhD candidate in Dr. Richard Austin's laboratory, demonstrates that mice on a high-fat diet – which causes obesity and fatty liver disease – also display similar reductions in TDAG51 protein examined in the liver. She further demonstrates that increasing the levels of TDAG51 in the livers of obese mice improved metabolic outcomes and insulin sensitivity. These studies suggest that the maintenance of this liver protein may represent a viable therapeutic strategy for the treatment of obesity associated with Non-Alcoholic Fatty Liver Disease (NAFLD). Tamana's research focuses on examining endoplasmic reticulum stress pathways to find novel treatment strategies aimed at reducing obesity, diabetes, and metabolic dysfunction-associated fatty liver disease. She will be defending her PhD thesis in July. #PhDcandidate #research #liverdisease #NAFLD #NASH #healthscience #TDAG51

New year, new updates! 🎉 Today we announced #TargetRWE's novel #PrecisionMedicine Platform to undertake growing unmet medical needs in #LiverDisease, #Gastroenterology, and Immune-mediated Inflammatory Conditions. Learn about our 150,000+ biospecimen samples 👉 https://prn.to/4aHlmuF #PrecisionMedicine #RealWorldEvidence #RWE #RealWorldData #ClinicalResearch #DataAnalytics #GenomicResearch #PredictiveAnalytics #DiseaseProgression #PredictiveModeling Derek Evans

Pathophysiology of policystic liver disease

Delve into the commentary by our Scientific Officer, Dr. Marco Alings, exploring the intricate relationship between MASLD and cardiometabolic health. Read more here: https://lnkd.in/d_QAH32A.

Clinicians with an interest in thrombophilia: Attend our next NBCA Journal Club session! The NBCA Journal Club highlights groundbreaking research in thrombosis and thrombophilia and features a manuscript author as part of the discussion. Our next session convenes June 18, 2024 from 2-3 p.m. ET to discuss, "Antithrombin Therapy: Current State and Future Outlook," published in Clinical and Applied Thrombosis/Hemostasis in 2023. The paper’s author, George M. Rodgers, III, MD, PhD, Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah School of Medicine, will join us to discuss his research. The session’s learning objectives: - Understand the genetic and acquired factors contributing to antithrombin (AT) deficiency and its implications. - Explore current treatment strategies for managing AT deficiency. - Identify specific patient populations and use cases where AT therapy may be considered and evaluate its potential benefits. - Investigate advancements and future directions in research, diagnosis, and treatment approaches for AT deficiency to enhance clinical outcomes and patient care. Register: bit.ly/NBCAJournalClub2024 #stoptheclot #nbcajounalclub #bloodclots #thrombophilia #thrombosis #antithrombintherapy #antithrombindeficiency #bloodcloteducation #continuingeducation

Mitochondrial Medicine. The GENOMIT initiative Pisa, November 17 – 18, 2023 This conference, based on the experience of the GENOMIT consortium, funded by the European Joint Programme on rare diseases, aims to bring different international groups together, exploring the most recent advances in term of natural histories, artificial intelligence, clinical trial readiness and emerging treatment options in preclinical and clinical models of mitochondrial diseases. https://lnkd.in/eXZ4Eqkm

In this episode (#302) of The Drive, I speak with Julia Wattacheril, M.D., M.P.H., a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. We delve deep into the complex world of liver health, beginning with a foundational overview of liver physiology. Julia provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. Here’s a glimpse of what we discuss: - The complex and crucial functionality of the liver, its four most essential functions, and more - Methods of diagnosing liver disease and how insights guide treatment and management strategies - Potential impact of recreational drugs, statins, and other medications on liver function test results - The impact of fructose consumption on liver health and the challenges of disentangling its effects from other factors like obesity and insulin resistance - Emerging drugs and therapies for addressing fat accumulation and fibrosis related to MAFLD - More https://bit.ly/3V6pnCU